Several studies have demonstrated the synergistic effect between antiangiogenic agents and PD-1/PD-L1 inhibitors in solid tumors, including renal cancer, non-small lung cancer, and endometrial cancer [23–27]. The gene discussed is CD274; the disease is renal carcinoma.